Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helmut Butzkueven

Showing results (181-190 of 390) with videos related to

Pageof 39
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 13, 2021
The effect of national disease-modifying therapy subsidy policy on long-term disability outcomes in people with multiple sclerosisSuzi B Claflin, Julie A Campbell, Deborah F Mason, et al.
Journal of Neuroscience Research|March 12, 2014
Ceruloplasmin gene-deficient mice with experimental autoimmune encephalomyelitis show attenuated early disease evolutionMelissa M Gresle, Katrin Schulz, Anna Jonas, et al.
Journal of Neuroscience Methods|September 24, 2018
Validation of a precision tremor measurement system for multiple sclerosisThushara Perera, Wee-Lih Lee, Shivanthan A C Yohanandan, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 10, 2006
Suppressor of cytokine signaling 3 limits protection of leukemia inhibitory factor receptor signaling against central demyelinationBen Emery, Holly S Cate, Mark Marriott, et al.
The Lancet. Neurology|April 28, 2022
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trialJohn F Foley, Gilles Defer, Lana Zhovtis Ryerson, et al.
Plos One|February 8, 2013
EphA4 receptor tyrosine kinase is a modulator of onset and disease severity of experimental autoimmune encephalomyelitis (EAE)Kathryn M Munro, Kirsty J Dixon, Melissa M Gresle, et al.
Clinical Epidemiology|October 22, 2024
Harmonized Data Quality Indicators Maintain Data Quality in Long-Term Safety Studies Using Multiple Sclerosis Registries/Data Sources: Experience from the CLARION StudyJan Hillert, Helmut Butzkueven, Melinda Magyari, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 13, 2020
Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudyNathaniel Lizak, Suzanne Hodgkinson, Ernest Butler, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 21, 2024
No evidence for association between rs10191329 severity locus and longitudinal disease severity in 1813 relapse-onset multiple sclerosis patients from the MSBase registryMaria Pia Campagna, Eva Kubala Havrdova, Dana Horakova, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|September 23, 2022
Using the EQ-5D-5L to investigate quality-of-life impacts of disease-modifying therapy policies for people with multiple sclerosis (MS) in New ZealandSuzi Claflin, Julie A Campbell, Richard Norman, et al.
Pageof 39

Showing results (181-190 of 390) with videos related to

Sort By:
Pageof 39
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 13, 2021
The effect of national disease-modifying therapy subsidy policy on long-term disability outcomes in people with multiple sclerosisSuzi B Claflin, Julie A Campbell, Deborah F Mason, et al.
Journal of Neuroscience Research|March 12, 2014
Ceruloplasmin gene-deficient mice with experimental autoimmune encephalomyelitis show attenuated early disease evolutionMelissa M Gresle, Katrin Schulz, Anna Jonas, et al.
Journal of Neuroscience Methods|September 24, 2018
Validation of a precision tremor measurement system for multiple sclerosisThushara Perera, Wee-Lih Lee, Shivanthan A C Yohanandan, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 10, 2006
Suppressor of cytokine signaling 3 limits protection of leukemia inhibitory factor receptor signaling against central demyelinationBen Emery, Holly S Cate, Mark Marriott, et al.
The Lancet. Neurology|April 28, 2022
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trialJohn F Foley, Gilles Defer, Lana Zhovtis Ryerson, et al.
Plos One|February 8, 2013
EphA4 receptor tyrosine kinase is a modulator of onset and disease severity of experimental autoimmune encephalomyelitis (EAE)Kathryn M Munro, Kirsty J Dixon, Melissa M Gresle, et al.
Clinical Epidemiology|October 22, 2024
Harmonized Data Quality Indicators Maintain Data Quality in Long-Term Safety Studies Using Multiple Sclerosis Registries/Data Sources: Experience from the CLARION StudyJan Hillert, Helmut Butzkueven, Melinda Magyari, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 13, 2020
Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudyNathaniel Lizak, Suzanne Hodgkinson, Ernest Butler, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 21, 2024
No evidence for association between rs10191329 severity locus and longitudinal disease severity in 1813 relapse-onset multiple sclerosis patients from the MSBase registryMaria Pia Campagna, Eva Kubala Havrdova, Dana Horakova, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|September 23, 2022
Using the EQ-5D-5L to investigate quality-of-life impacts of disease-modifying therapy policies for people with multiple sclerosis (MS) in New ZealandSuzi Claflin, Julie A Campbell, Richard Norman, et al.
Pageof 39